A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser(Institute of Cancer Research), Nicholas C. Turner(Royal Marsden NHS Foundation Trust)
Cited by 323
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2022|633
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
|Nature Communications|2020|258
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
|Annals of Oncology|2022|184
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
|Clinical Cancer Research|2019|136